SPILLO reveals how molecules interact across the proteome using a unique proprietary physics-based in silico technology. Unbiased target and off-target identification uncovers mechanisms behind therapeutic and adverse effects, reveals new therapeutic opportunities, and increases drug asset value.
Products, services, technology
Proteome-wide target and off-target identification for small molecules and selected modalities. SPILLO uncovers protein interactions, including unexpected ones at hidden or hard-to-detect binding sites. Validated results led to peer-reviewed work, new IP, funding, and independent database curation.
Cooperation possibilities
Project-based collaborations with pharmaceutical and biotech companies, asset owners, licensing and business development teams, and research organizations seeking deeper molecular insight into drug assets for R&D, de-risking, repurposing, mechanism elucidation, and molecular due-diligence support.
- https://www.spillo.ch
- +41 76 626 83 00
- Send an email
- Alessandro Di Domizio
Some insights
By uncovering the biomolecular mechanisms behind drug efficacy and adverse effects, SPILLO helps make medicines safer, more effective, and better targeted. Mechanistic insight enables earlier risk reduction, fewer late-stage failures, and more informed, patient-tailored development strategies.
We are proud that SPILLO’s predictions have been experimentally validated in independent studies and published in peer-reviewed journals, demonstrating the ability to address complex real-world drug R&D challenges—particularly in high-risk programs—that remain unresolved with existing approaches.
We look up to organizations that combine scientific rigor with responsibility, transparency, and long-term impact—advancing drug development through deep and reliable mechanistic understanding.
By facilitating qualified connections with pharmaceutical, biotech, and government research organizations facing complex mechanistic, efficacy, or safety challenges in applied drug development, and by ensuring visibility among R&D decision-makers.
Pharmaceutical and biotech R&D, translational science, and drug safety teams, as well as public or government research institutes engaged in applied drug development programs for small-molecule therapeutics.